The fourth edition of the India Pharmaceutical Forum, to be held in Mumbai during February 27-28, will see deliberations on several industry-related topics, besides the key focus area of quality. With participation expected from at least five global regulatory authorities, audiences are set to get insights on contemporary concerns for the industry, including the impact of Brexit and the Valsartan recalls, and the lessons to be learnt from the incident. Other sessions to watch out for include one on disruptive technologies in pharmaceutical operations, besides a couple of experience showcases involving Cadila Healthcare and Sun Pharmaceuticals.

Understanding global quality requirements has become a critical part of the pharma industry’s operations as it exports to major developed markets and as a result comes under intense scrutiny of global regulators. As always, the CEO panel at the close of the session is expected to be a major draw as it features the top brass from India’s biggest drugmakers, including Sun Pharma, Cipla, Lupin, Dr Reddy’s, Cadila and Torrent.